Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA).
Tandstad T, Ståhl O, Dahl O, Haugnes HS, Håkansson U, Karlsdottir Å, Kjellman A, Langberg CW, Laurell A, Oldenburg J, Solberg A, Söderström K, Stierner U, Cavallin-Ståhl E, Wahlqvist R, Wall N, Cohn-Cedermark G; SWENOTECA. Tandstad T, et al. Among authors: stierner u. Ann Oncol. 2016 Jul;27(7):1299-304. doi: 10.1093/annonc/mdw164. Epub 2016 Apr 6. Ann Oncol. 2016. PMID: 27052649 Free article.
Risk-adapted treatment of clinical stage 1 non-seminoma testis cancer.
Klepp O, Dahl O, Flodgren P, Stierner U, Olsson AM, Oldbring J, Nilsson S, Daehlin L, Tørnblom M, Småland R, Starkhammar H, Abramsson L, Wist E, Raabe N, Edekling T, Cavallin-Ståhl E. Klepp O, et al. Among authors: stierner u. Eur J Cancer. 1997 Jun;33(7):1038-44. doi: 10.1016/s0959-8049(97)00041-5. Eur J Cancer. 1997. PMID: 9376184
Long-term follow-up after risk-adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study.
Tandstad T, Cohn-Cedermark G, Dahl O, Stierner U, Cavallin-Stahl E, Bremnes RM, Klepp O. Tandstad T, et al. Among authors: stierner u. Ann Oncol. 2010 Sep;21(9):1858-1863. doi: 10.1093/annonc/mdq026. Epub 2010 Feb 8. Ann Oncol. 2010. PMID: 20142410 Free article. Clinical Trial.
Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial.
Hansson J, Aamdal S, Bastholt L, Brandberg Y, Hernberg M, Nilsson B, Stierner U, von der Maase H; Nordic Melanoma Cooperative Group. Hansson J, et al. Among authors: stierner u. Lancet Oncol. 2011 Feb;12(2):144-52. doi: 10.1016/S1470-2045(10)70288-6. Epub 2011 Jan 20. Lancet Oncol. 2011. PMID: 21256809 Clinical Trial.
Population-based study of treatment guided by tumor marker decline in patients with metastatic nonseminomatous germ cell tumor: a report from the Swedish-Norwegian Testicular Cancer Group.
Olofsson SE, Tandstad T, Jerkeman M, Dahl O, Ståhl O, Klepp O, Bremnes RM, Cohn-Cedermark G, Langberg CW, Laurell A, Solberg A, Stierner U, Wahlqvist R, Wijkström H, Anderson H, Cavallin-Ståhl E. Olofsson SE, et al. Among authors: stierner u. J Clin Oncol. 2011 May 20;29(15):2032-9. doi: 10.1200/JCO.2010.29.1278. Epub 2011 Apr 11. J Clin Oncol. 2011. PMID: 21482994 Clinical Trial.
69 results